Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity

American Journal of Cardiology

Volumn 112, Issue 12, 2013, Pages 1980-1984

  Lotrionte, Marzia ^a   Biondi Zoccai, Giuseppe ^b   Abbate, Antonio ^c   Lanzetta, Gaetano ^d   D'Ascenzo, Fabrizio ^e   Malavasi, Vincenzo ^f   Peruzzi, Mariangela ^b   Frati, Giacomo ^b   Palazzoni, Giovanni ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d Italian Neurotraumatologic Institute   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; ANTINEOPLASTIC ANTIBIOTIC;

BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CHEST RADIOTHERAPY; FEMALE; HODGKIN DISEASE; HUMAN; LEUKEMIA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RADIOTHERAPY; REVIEW; RISK ASSESSMENT; SOLID TUMOR; COMORBIDITY; DRUG EFFECTS; HEART; INCIDENCE; META ANALYSIS; NEOPLASMS; RISK FACTOR;

ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; COMORBIDITY; DOXORUBICIN; HEART; HUMANS; INCIDENCE; NEOPLASMS; RISK FACTORS;

EID: 84888644213     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2013.08.026     Document Type: Review

References (33)

1. K. Shan, A.M. Lincoff, and J.B. Young Anthracycline-induced cardiotoxicity Ann Intern Med 125 1996 47 58
2. D. Cardinale, A. Colombo, M.T. Sandri, G. Lamantia, N. Colombo, M. Civelli, G. Martinelli, F. Veglia, C. Fiorentini, and C.M. Cipolla Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition Circulation 114 2006 2474 2481
3. M. Lotrionte, G. Palazzoni, R. Natali, G. Comerci, A. Abbate, F. Loperfido, and G. Biondi-Zoccai Assessment of left ventricular systolic dysfunction by tissue Doppler imaging to detect subclinical cardiomyopathy early after anthracycline therapy Minerva Cardioangiol 55 2007 711 720
4. G.T. Armstrong, C.A. Sklar, M.M. Hudson, and L.L. Robison Long-term health status among survivors of childhood cancer: does sex matter? J Clin Oncol 25 2007 4477 4489
5. M. Lotrionte, E. Cavarretta, A. Abbate, E. Mezzaroma, E. De Marco, S. Di Persio, F. Loperfido, G. Biondi-Zoccai, G. Frati, and G. Palazzoni Temporal changes in standard and tissue Doppler imaging echocardiographic parameters after anthracycline chemotherapy in women with breast cancer Am J Cardiol 112 2013 1005 1012
6. N.L. Wilczynski, R.B. Haynes for the Hedges Team Developing optimal search strategies for detecting clinically sound prognostic studies in MEDLINE: an analytic survey BMC Med 2 2004 23
7. G. Biondi-Zoccai, E. Romagnoli, P. Agostoni, D. Capodanno, D. Castagno, F. D'Ascenzo, G. Sangiorgi, and M.G. Modena Are propensity scores really superior to standard multivariable analysis? Contemp Clin Trials 32 2011 731 740
8. A. Stang Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses Eur J Epidemiol 25 2010 603 605
9. G.G. Biondi-Zoccai, M. Lotrionte, C. Moretti, E. Meliga, P. Agostoni, M. Valgimigli, A. Migliorini, D. Antoniucci, D. Carrié, G. Sangiorgi, A. Chieffo, A. Colombo, M.J. Price, P.S. Teirstein, E.H. Christiansen, A. Abbate, L. Testa, J.P. Gunn, F. Burzotta, A. Laudito, G.P. Trevi, and I. Sheiban A collaborative systematic review and meta-analysis on 1278 patients undergoing percutaneous drug-eluting stenting for unprotected left main coronary artery disease Am Heart J 155 2008 274 283
10. B.M. Aleman, A.W. van den Belt-Dusebout, M.L. De Bruin, M.B. van 't Veer, M.H. Baaijens, J.P. de Boer, A.A. Hart, W.J. Klokman, M.A. Kuenen, G.M. Ouwens, H. Bartelink, and F.E. van Leeuwen Late cardiotoxicity after treatment for Hodgkin lymphoma Blood 109 2007 1878 1886
11. J.R. Andolina, and K. Dilley Anthracycline-induced cardiac toxicity more likely in underweight childhood cancer survivors J Pediatr Hematol Oncol 32 2010 411 415
12. C.A. Brouwer, A. Postma, J.M. Vonk, N. Zwart, M.P. van den Berg, M.T. Bink-Boelkens, W.V. Dolsma, A.J. Smit, E.G. de Vries, W.J. Tissing, and J.A. Gietema Systolic and diastolic dysfunction in long-term adult survivors of childhood cancer Eur J Cancer 47 2011 2453 2462
13. G. Dranitsaris, D. Rayson, M. Vincent, J. Chang, K. Gelmon, D. Sandor, and G. Reardon The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines Breast Cancer Res Treat 107 2008 443 450
14. X.L. Du, R. Xia, C.C. Liu, J.N. Cormier, Y. Xing, D. Hardy, W. Chan, and K. Burau Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer Cancer 115 2009 5296 5308
15. D.L. Hershman, R.B. McBride, A. Eisenberger, W.Y. Tsai, V.R. Grann, and J.S. Jacobson Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma J Clin Oncol 26 2008 3159 3165
16. M.M. Hudson, S.N. Rai, C. Nunez, T.E. Merchant, N.M. Marina, N. Zalamea, C. Cox, S. Phipps, R. Pompeu, and D. Rosenthal Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors J Clin Oncol 25 2007 3635 3643
17. J.P. Krischer, S. Epstein, D.D. Cuthbertson, A.M. Goorin, M.L. Epstein, and S.E. Lipshultz Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience J Clin Oncol 15 1997 1544 1552
18. S. Myrehaug, M. Pintilie, R. Tsang, R. Mackenzie, M. Crump, Z. Chen, A. Sun, and D.C. Hodgson Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy Leuk Lymphoma 49 2008 1486 1493
19. M. Ryberg, D. Nielsen, G. Cortese, G. Nielsen, T. Skovsgaard, and P.K. Andersen New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients J Natl Cancer Inst 100 2008 1058 1067
20. S.E. Sallan, and L.A. Clavell Cardiac effects of anthracyclines used in the treatment of childhood acute lymphoblastic leukemia: a 10-year experience Semin Oncol 11 1984 19 21
21. G. Schellong, M. Riepenhausen, C. Bruch, S. Kotthoff, J. Vogt, T. Bölling, K. Dieckmann, R. Pötter, A. Heinecke, J. Brämswig, and W. Dörffel Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies Pediatr Blood Cancer 55 2010 1145 1152
22. L.J. Steinherz, P.G. Steinherz, C.T. Tan, G. Heller, and M.L. Murphy Cardiac toxicity 4 to 20 years after completing anthracycline therapy JAMA 266 1991 1672 1677
23. S.M. Swain, F.S. Whaley, and M.S. Ewer Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials Cancer 97 2003 2869 2879
24. E. Tan-Chiu, G. Yothers, E. Romond, C.E. Geyer Jr., M. Ewer, D. Keefe, R.P. Shannon, S.M. Swain, A. Brown, L. Fehrenbacher, V.G. Vogel, T.E. Seay, P. Rastogi, E.P. Mamounas, N. Wolmark, and J. Bryant Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31 J Clin Oncol 23 2005 7811 7819
25. H.J. van der Pal, E.C. van Dalen, M. Hauptmann, W.E. Kok, H.N. Caron, C. van den Bos, F. Oldenburger, C.C. Koning, F.E. van Leeuwen, and L.C. Kremer Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study Arch Intern Med 170 2010 1247 1255
26. H. Visscher, C.J. Ross, S.R. Rassekh, A. Barhdadi, M.P. Dubé, H. Al-Saloos, G.S. Sandor, H.N. Caron, E.C. van Dalen, L.C. Kremer, H.J. van der Pal, A.M. Brown, P.C. Rogers, M.S. Phillips, M.J. Rieder, B.C. Carleton, M.R. Hayden Canadian Pharmacogenomics Network for Drug Safety Consortium Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children J Clin Oncol 30 2012 1422 1428
27. D.D. Von Hoff, M.W. Layard, P. Basa, H.L. Davis Jr., A.L. Von Hoff, M. Rozencweig, and F.M. Muggia Risk factors for doxorubicin-induced congestive heart failure Ann Intern Med 91 1979 710 717
28. M. Lotrionte, G. Palazzoni, R. Natali, G. Comerci, A. Abbate, S. Di Persio, and G.G. Biondi-Zoccai Appraising cardiotoxicity associated with liposomal doxorubicin by means of tissue Doppler echocardiography end-points: rationale and design of the LITE (Liposomal doxorubicin-Investigational chemotherapy-Tissue Doppler imaging Evaluation) randomized pilot study Int J Cardiol 135 2009 72 77
29. L.C. Kremer, E.C. van Dalen, M. Offringa, and P.A. Voûte Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review Ann Oncol 13 2002 503 512
30. L.C. Kremer, H.J. van der Pal, M. Offringa, E.C. van Dalen, and P.A. Voûte Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review Ann Oncol 13 2002 819 829
31. F. D'Ascenzo, E. Cavallero, G. Biondi-Zoccai, C. Moretti, P. Omedè, M. Bollati, D. Castagno, M.G. Modena, F. Gaita, and I. Sheiban Use and misuse of multivariable approaches in interventional cardiology studies on drug-eluting stents: a systematic review J Interv Cardiol 25 2012 611 621
32. M. Lotrionte, G. Palazzoni, A. Abbate, E. De Marco, E. Mezzaroma, S. Di Persio, G. Frati, F. Loperfido, and G. Biondi-Zoccai Cardiotoxicity of a non-pegylated liposomal doxorubicin-based regimen versus an epirubicin-based regimen for breast cancer: the LITE (Liposomal doxorubicin-Investigational chemotherapy-Tissue Doppler imaging Evaluation) randomized pilot study Int J Cardiol 167 2013 1055 1057
33. X. Bosch, M. Rovira, M. Sitges, A. Domènech, J.T. Ortiz-Pérez, T.M. de Caralt, M. Morales-Ruiz, R.J. Perea, M. Monzó, and J. Esteve Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies) J Am Coll Cardiol 61 2013 2355 2362